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Human sialic acid O-acetyl esterase 
(sIAe) – mediated changes in 
sensitivity to etoposide in a 
medulloblastoma cell line
Rebecca L. Mather1,2, Katie F. Loveson  1 & Helen L. Fillmore  1
Medulloblastoma (MB), the most common malignant paediatric brain tumour occurs in the cerebellum. 
Advances in molecular genomics have led to the identification of defined subgroups which are 
associated with distinct clinical prognoses. Despite this classification, standard therapies for all 
subgroups often leave children with life-long neurological deficits. New therapeutic approaches are 
therefore urgently needed to reduce current treatment toxicity and increase survival for patients. GD3 
is a well-studied ganglioside which is known to have roles in the development of the cerebellum. Post-
partum GD3 is not highly expressed in the brain. In some cancers however GD3 is highly expressed. 
In MB cells GD3 is largely acetylated to GD3A. GD3 is pro-apoptotic but GD3A can protect cells from 
apoptosis. Presence of these gangliosides has previously been shown to correlate with resistance to 
chemotherapy. Here we show that the GD3 acetylation pathway is dysregulated in MB and as a proof-
of-principle we show that increased GD3 expression sensitises an MB cell line to etoposide.
Medulloblastoma (MB) is the most common malignant brain tumour of childhood and remains the leading cause 
of cancer-related mortality in children up to the age of fourteen1. MBs arise in the cerebellum and can spread to 
the spinal cord. Although recent studies have identified multiple subgroups, four distinct molecular subgroups 
have been defined and are now recognised by the World Health Organisation. The major subgroups consist of 
WNT, SHH, Group 3 and Group 42–5.
Despite a reported survival rate of >5 years post-diagnosis of 80.1%, (60–70% for high-risk children)3,6, 
a proportion of patients remain incurable due to leptomeningeal dissemination7,8. Where MB survival can 
be achieved, it is often accompanied with a severe impact on the patient’s quality of life. This impact is due to 
treatment-induced life-long neurological deficits and endocrine disorders9. Novel therapeutic strategies are there-
fore urgently needed to improve survival for patients, and to improve quality of life for survivors.
Gangliosides are glycosphingolipids which contain at least one sialic acid residue in their oligosaccharide 
chain10. Gangliosides have been shown to have diverse roles in physiology, and pathology (including cancer)11. 
One of the most characterized gangliosides in the brain is GD312–14. GD3 is a predominant ganglioside in neural 
stem cells, where it has been shown to play a role in proliferation via epidermal growth factor receptor signal-
ing15. GD3 and its acetylated form GD3A are both known to be expressed by granule neuron precursors (GPCs) 
during cerebellar development16, and these cells are implicated in the pathology of SHH MB17. In rats, GD3A is 
particularly enriched at sites of axonal contact between cells of the external granule layer and molecular layer18. 
Post-partum GD3 accumulates within the supernumerary GPCs and causes mitochondria-mediated apopto-
sis19–21. Expression of GD3 in the post-partum brain is virtually absent22,23 however in some cancers of neural 
crest origin, such as malignant melanoma, and glioblastoma (GBM)24–26 these gangliosides are expressed. GD3A 
has been has been shown to prevent GD3 from its apoptotic-associated role27 and in addition, has been implicated 
in leukemia to confer resistance to chemotherapeutic agents28.
GD3 and GD3A can exist in a delicate balance between pro-apoptotic GD3 and pro-survival GD3A 24,29. Two 
enzymes are responsible for the turnover of these gangliosides. The GD3 acetylation enzyme remains elusive, 
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however there is some evidence that Cas 1 domain containing 1 (Casd1)30,31 is the enzyme responsible for this 
process. The GD3A deacetylation enzyme is known to be sialic acid O-acetyl esterase (SIAE)32,33. As GD3A is 
thought to protect cells from mitochondria-mediated apoptosis, we designed proof-of-concept experiments to 
determine if deacetylation of GD3A by SIAE would result in increased GD3, and cause cells to become apoptotic 
or sensitise them to existing chemotherapies.
Results
Expression of CASD1 and SIAE varies according to molecular subgroup. We first sought to exam-
ine the expression of genes involved in the acetylation and deacetylation of GD3 in MB using publicly available 
data from the R2 database (r2.amc.nl); the details of individual datasets used can be found in materials and meth-
ods. The components of the GD3 pathway are summarised in Fig. 1A. Briefly, GD3 is synthesised by the enzyme 
GD3 synthase. GD3 can then be acetylated by the enzyme CASD1, and deacetylated by the enzyme SIAE.
We next analysed data from non-neoplastic cerebellar samples obtained at autopsy (Roth GSE3526)34 and 
compared expression with MB. Expression of CASD1 was significantly up-regulated in MB samples (Fig. 1B 
p < 0.0001). In contrast SIAE, GD3’s deacetylation enzyme was significantly down-regulated in MB samples 
(Fig. 1C p = 0.0005). Due to chip types we were unable to corroborate this data using other datasets. Next, to 
determine if CASD1 and SIAE were dysregulated according to subgroup we used the largest dataset available 
which has samples with annotated molecular subgroups (Northcott (GSE21140))35. CASD1 was found to be 
highest in group 4. Further to this, expression of CASD1 in groups 3 and 4 was significantly higher than WNT 
(p < 0.0001; Fig. 1D), significantly higher in group 4 compared to SHH (p < 0.0001; Fig. 1C), and expression was 
also higher in group 4 compared to group 3 (p = 0.0221). Finally, and in contrast, expression of SIAE was shown 
to be significantly lower in SHH (p < 0.0001), group 3 (p = 0.0042) and group 4 (p < 0.0031) compared to WNT 
patients (Fig. 1E). The data from Fig. 1D,E was then analysed to generate a ratio of expression between CASD1 
and SIAE for each sample (Fig. 1F). This data demonstrates that there is a significant inverse-correlation between 
CASD1 and SIAE expression in SHH, group 3, and group 4 subgroups when compared to WNT (SHH p = 0.0003; 
Figure 1. Expression of GD3 acetylation pathway components in clinical MB samples. (A) Schematic of the 
GD3 acetylation pathway shows the roles of GD3 synthase, SIAE and CASD1 in the synthesis and turnover of 
GD3 and GD3A. (B) Expression of CASD1, encoding the enzyme that converts GD3 to GD3A is upregulated in 
MB samples (Pfister dataset) compared to non-neoplastic cerebellum (Roth dataset; p < 0.0001). (C) Expression 
of SIAE, encoding the enzyme which deacetylates GD3A to GD3 is significantly down-regulated in MB samples 
(Pfister dataset) compared to non-neoplastic cerebellum (Roth dataset; p = 0.0005). (D) Expression of CASD1 
is highest in group 4 samples when compared to WNT and SHH (p < 0.0001), and group 3 (p = 0.0221). The 
expression of CASD1 is also significantly higher in group 3 compared to WNT (p = 0.00403). (E) Expression 
of SIAE, is significantly higher in WNT tumours compared to SHH (p < 0.0001), group 3 (p = 0.00043), and 
group 4 (p = 0.0031). Data obtained from the R2 database using the Northcott data set (gse21140). (F) The data 
from D and E analysed to generate a ratio of expression between CASD1 and SIAE for each sample. There is a 
significant inverse-correlation between CASD1 and SIAE expression in SHH, group 3, and group 4 subgroups 
when compared to WNT (SHH p = 0.0003; Group 3 p = −0.0008; Group 4 p < 0.0001). Data was analysed by (B 
and C) two-tailed unpaired t-test; (D–F) one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
comparisons post hoc test using graph pad prism 6 software. (*p < 0.05; **p < 0.01; ****p < 0.0001).
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Group 3 p = −0.0008; Group 4 p < 0.0001). This data was further corroborated using all publicly available data-
sets on the R2 database which contained samples annotated by molecular subgroup (Supplementary Fig. 1).
GD3 and GD3A are expressed in MB cell lines. As we have determined the expression of GD3 pathway 
components in MB clinical samples was dysregulated, we sought to determine the function of this pathway using 
in vitro models of MB. Expression of GD3 and GD3A in MB was then investigated using established cell lines. 
Flow cytometric analysis of GD3 and GD3A showed that the population of cells expressing GD3 was similar 
for the three cell lines RES256, UW402 and CHLA-01-Med (56.7%, 61.3% and 45.1% respectively; Fig. 2). The 
percentage of the cells expressing GD3A was also found to be similar between the cell lines (85.4%, 74.4% and 
79.4% respectively; Fig. 2). Expression of GD3A was slightly, but not significantly, higher than GD3 expression 
in RES256 and UW402, (85.4% and 74.4% respectively), however GD3A expression was significantly higher in 
CHLA-01-Med (79.4%, Fig. 2 p = 0.0305).
Induction of SIAE in RES256 cells. SIAE is responsible for the deacetylation of 9-O-acetylated sialic acid 
residues such as those found in GD3A32. We hypothesised that deacetylation of GD3A would increase GD3 levels 
and therefore induce mitochondria-mediated apoptosis. To investigate this premise, an inducible system was used 
to induce SIAE expression in the MB cell line RES256. SIAE expression was found low in RES256 cells without 
SIAE overexpression, which was expected based on the previous bioinformatic analyses. Following validation of 
expression, one EGFP vector control clone, two wild-type SIAE clones, and one previously described SIAE cat-
alytically inactive mutant (S127A)33 clone were maintained for subsequent experiments. Transcription of genes 
were confirmed indirectly via expression of EGFP (Supplementary Fig. 2). SIAE expression was induced for 48 h 
with doxycycline and confirmed by western blot analysis (Fig. 3). We found SIAE expression to be undetectable 
Figure 2. Expression of GD3 and GD3A was confirmed by flow cytometry. Intracellular expression of GD3 and 
GD3A demonstrates a significantly higher percentage of cells expressing GD3A compared to GD3 in CHLA-01-
Med (p = 0.0011). Data analysed by unpaired two-tailed t-test using Graph Pad Prism 6 software (**p < 0.01; 
***p < 0.001) n = 3 ± SEM.
Figure 3. SIAE expression is induced by stable tet-responsive RES256 cells. RES256 cells were cultured in 
the presence (+) and absence (−) of doxycycline (dox) for 48 hours and analysed by western blot. SIAE was 
expressed by two wild-type clones, SIAE 1 and SIAE 2, and by the catalytic mutant, S127A. Importantly only 
when the cells were cultured with doxycycline for 48 hours was SIAE expressed. Equal protein loading between 
samples from each clone are confirmed with beta actin. A further immuno-reactive band of approximately 
32 kDa for SIAE was seen (Supplementary Fig. 3). The identity of this band is unknown. Less protein was loaded 
in the S127A samples due to protein concentration of the lysate. Image acquired using the Licor Odyssey Clx 
equipped with ImageStudio 5 software. Representative image of n = 2.
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at the protein level in RES256 cells without doxycycline addition, which was unsurprising based on bioinfor-
matic analyses of MB tissue (Fig. 1 and Supplementary Fig. 1). SIAE is predicted to have a molecular weight of 
62 kDa and this was confirmed. Western blot analysis also demonstrated no SIAE expression by EGFP clones 
when treated with doxycycline (Fig. 3). SIAE clones 1 and 2 express SIAE only in the presence of doxycycline. 
Interestingly, the catalytically mutated S127A clone, when treated with doxycycline, expressed more SIAE protein 
than the WT clones. The reason for this is currently unknown.
SIAE expression increases esterase activity in RES256 cells. To determine if the induced SIAE was 
functional in RES256 cells, esterase activity was investigated using the esterase substrate 4-nitrophenol (pNP). 
The vector control (EGFP) and the catalytic mutant (S127A) clone showed no increase in esterase activity follow-
ing induction with doxycycline (p > 0.05; Fig. 4). Both wild-type SIAE clones 1 and 2 demonstrated a significantly 
increased esterase activity when treated with 0.2 mM pNP, only when cells were treated with doxycycline (SIAE 1 
p = 0.0447; SIAE 2 p = 0.0434). These data are supported by the protein expression data shown in Fig. 3 demon-
strating that the expressed enzyme is functional, and that the catalytically dead mutant S127A (nor EGFP) has no 
significant effect on esterase activity.
SIAE expression leads to an increase in GD3 in one of two clones. We then investigated the effects 
of SIAE induction on GD3A and GD3 levels. Surprisingly GD3A expression did not change in RES256 SIAE clones 
despite SIAE expression being induced by doxycycline (Fig. 5A). There was however a significant decrease in 
GD3A in the EGFP vector control clone (Fig. 5A), the reason for which is currently unknown. Expression in the 
Figure 4. Esterase activity is increased with SIAE induction. Total esterase activity was investigated using an 
esterase substrate (pNP) assay. Expression of SIAE was induced in RES256 cells for 48 hours using doxycycline. 
RES256 cells were treated with 0.2 mM pNP in the presence and absence of doxycycline. Only SIAE expressing 
clones demonstrated a significant increase in esterase activity with induction of expression, SIAE 1 (p = 0.0447) 
and SIAE 2 (p = 0.0434). No significant increases in activity were seen with induction of EGFP or S127A clones 
(p > 0.05). Data analysed by one-way analysis of variance (ANOVA) and Siddak post-hoc test using GraphPad 
Prism 6 software n = 3.
Figure 5. GD3 expression is increased with SIAE induction in RES256 cells. (A) Using flow cytometry 
expression of GD3A was found to be significantly reduced in EGFP expressing controls (p < 0.0180). No 
difference was seen in SIAE clones 1, 2 or S127A. (B) GD3 expression was significantly increased in SIAE clone 
2 (p = 0.0171). No significant changes are seen in SIAE 1, S127A or EGFP expressing cells. SIAE expression was 
induced for 48 hours with doxycycline. Samples were analysed using a multi-parameter fluorescence-activated 
cell sorting (FACS) Calibur flow cytometer and CellQuest Pro software. Data analysed by one-way analysis 
of variance followed by Tukey’s multiple comparisons post-hoc test using Graph Pad (*p < 0.05; **p < 0.01) 
n = 3 ± SEM.
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catalytically dead mutant remained unchanged. Despite no significant reduction in GD3A levels, GD3 expression 
was found to be significantly increased in SIAE clone 2, following addition of doxycycline (p = 0.0171; Fig. 5B). 
An increase in GD3 expression in SIAE expressing clone 1 failed to reach significance (Fig. 5B; p > 0.05 SIAE1). 
Despite the significant reduction of GD3A in EGFP clones, a subsequent increase in GD3 was not observed in 
these cells, nor was a significant change in GD3 expression in S127A cells (Fig. 5B).
SIAE induced expression leads to collapse of the mitochondrial membrane potential. We next 
explored the effects of SIAE induced expression on mitochondrial membrane potential using the JC-1 assay. 
Despite the differences seen in GD3 expression in the two SIAE clones (Fig. 5), there was a significant increase 
in the depolarisation of the mitochondrial membrane potential when SIAE expression was induced with doxy-
cycline (p = 0.0058 clone 1 and p = 0.0045 clone 2; Fig. 6A). In EGFP and S127A clones, induction of expression 
with doxycycline did not significantly affect the mitochondrial membrane potential (p > 0.05; Fig. 6A). These 
data suggest that SIAE induction may result in changes in the GD3 to GD3A ratio, and the increase in GD3 may 
result in a pro-apoptotic phenotype by mitochondrial membrane depolarisation. We then investigated if SIAE 
induction led to a commitment to cell death using the trypan blue exclusion method. In order to normalise for 
any differences in proliferation between clones, viable cells were counted just prior to doxycycline addition (0 h). 
After 96 hours the percentage of viable cells for each condition revealed that wild-type SIAE expression alone led 
to a significant reduction in cell viability (SIAE 1 p = 0.0173; SIAE 2 p = 0.0097) (Fig. 6B).
SIAE induction and sensitisation of cells to etoposide. We next sought to determine if SIAE could 
sensitise cells to etoposide, a chemotherapeutic with a shared mechanism of action to GD3. Etoposide is a com-
monly used chemotherapy for MB and is known to act in part by collapsing the mitochondrial membrane poten-
tial36. We therefore treated cells with etoposide to determine if induction of SIAE could sensitise cells. When 
clones were treated with various concentrations of etoposide for 72 hours there were no significant differences 
when SIAE expression was induced in any of the clones (p > 0.05; Fig. 7), except for SIAE clone 2, (p = 0.0034; 
Fig. 7). In these cells the IC50 was significantly reduced from 5.1 µM without induction to 1.9 µM with induction 
of SIAE expression (p = 0.0034; Fig. 7).
Discussion
Treatment protocols for MB often leave patients with significant treatment related sequelae, including neuro-
cognitive deficits, which severely impact quality of life9. There is a great need for novel therapeutic approaches, 
reducing the levels of toxicity arising from current treatments, and new therapeutic strategies aimed at specific 
MB subgroups. GD3, an oncofetal ganglioside, plays a critical role in development13,14,22,37. GD3 is expressed 
highly in several cancers where it is commonly acetylated to GD3A24,26,28,38–41. We determined that this pathway 
may have clinical relevance due to its dysregulation in MB compared to non-neoplastic cerebellum. It was found 
that expression the expression of CASD1 and SIAE are inversely correlated in MB subgroups groups 3 and 4, 
suggesting that the balance of GD3 to GD3A may play a role. As CASD1 is not the only enzyme shown to be capa-
ble of acetylating GD329 our efforts focused on deacetylation of GD3A by means of inducing expression of SIAE 
induction. The catalytic site of SIAE has been described previously, allowing us carry out a functional study using 
this enzyme and a catalytically dead mutant SIAE S127A42,43.
Figure 6. SIAE induction leads to mitochondrial membrane depolarisation in RES256 cells. (A) Status of 
the mitochondrial membrane potential was determined using the JC-1 assay after 48 hours of induction with 
doxycycline. Membrane polarisation was determined between cells cultured in the presence and absence of 
doxycycline as a ratio between red fluorescent signal (polarised) and green fluorescent signal (depolarised). 
Expression of wild-type SIAE significantly depolarises the mitochondrial membrane potential in clone 1 
(p = 0.0058) and clone 2 (p = 0.0045). Depolarisation did not occur in EGFP or S127A expressing clones 
(p > 0.05). (B) Trypan blue exclusion determined that SIAE wild-type clones have significantly reduced 
viability compared to non-induced controls (SIAE 1 p = 0.0173; SIAE 2 p = 0.0097). (A) Data analysed by one-
way analysis of variance (ANOVA) and Tukey’s post hoc test. (B) Data analysed using two-tailed t-test. Both 
analyses were carried out using GraphPad prism 6 software *p < 0.05; **p < 0.01), n = 3 ± SEM
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SIAE in its active form is a glycoprotein with a molecular weight of 62 kDa42. When SIAE and S127A were 
expressed in the RES256 cell line, the expression appeared to be somewhat different, even when considering 
that total protein loading was less for S127A. The active glycosylated form of SIAE was expressed by both SIAE 
clones. An additional immuno-reactive protein was seen at 32 kDa, which was intense for the SIAE clones and less 
intense for S127A. The identity of 32 kDa band is unknown. GD3A was significantly reduced upon doxycycline 
treatment in the EGFP clone, but none of the other clones demonstrated any significant differences. We also note 
that there was no decrease in GD3A expression with SIAE expression despite SIAE clone 2 having increased GD3. 
One possible explanation for this has been shown in studies using endogenous addition of GD3, in which authors 
demonstrated that GD3 can induce its own acetylation machinery44. We theorise that this could be replenishing 
the pool of GD3A and may help to explain our results.
GD3 expression has been shown to result in mitochondrial membrane depolarisation through trafficking to 
the mitochondrial membranes and the opening of the mitochondrial membrane permeability pore19–21. Induction 
of SIAE induction resulted in the collapse of the mitochondrial membrane potential suggesting that the increase 
in GD3 by SIAE was sufficient for this phenotype. We also demonstrate a commitment to apoptosis through 
trypan blue staining, suggestive of mitochondrial membrane potential collapse being a potential mechanism.
GD3A expression has previously been shown to correlate with chemo-resistant disease41. The treatment regime 
for MB includes lomustine, cyclophosphamide, vincristine, cisplatin, and etoposide, among others45. As a mecha-
nism of action of etoposide has been described in isolated mitochondria from Jurkat cells36 where the mitochon-
drial membrane potential was shown to collapse with high concentrations of etoposide (50 µM), we utilised this 
drug. Using clinically achievable doses of etoposide46 SIAE clone 2 was the only clone to demonstrate a reduced 
IC50 of etoposide, which may be as a result in a significant increase in GD3 expression. This data indicates a 
possible role for GD3 in chemo-sensitivity to etoposide, however further work is required to validate this as a 
mechanism of action.
Conclusion
The GD3 acetylation pathway is re-expressed in some malignancies including MB. It has been shown in various 
cancers to influence cell viability, invasion and chemo-resistance. Here we have conducted a ‘proof-of-principle’ 
study demonstrating that the GD3 acetylation pathway could be targeted as a potential therapeutic strat-
egy for paediatric MB as SIAE expression leads to changes in the GD3 to GD3A ratio which may lead to 
mitochondria-mediated apoptosis and etoposide sensitivity. Additional studies are required to further demon-
strate the mechanism of action of SIAE in chemo-resistance, invasion and its potential role in molecular 
subgroups.
Figure 7. Response to etoposide is altered in SIAE over-expressing cells. RES256 cells were exposed to 
etoposide for 72 hours after 48 hours of induction with SIAE. No significant differences in response to drug were 
seen with induction of expression (induced expression is shown in grey) in EGFP, SIAE 1 or S127A (p > 0.05), 
however the IC50 was significantly reduced from 5.1 μM (±1.3) to 1.9 μM (±0.9) in SIAE 2 (p = 0.0034). Data 
analysed using GraphPad Prism 6 software using sigmoidal dose-response comparison analysis. Data presented 
as mean ± SEM n = 3.
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Materials and Methods
Bioinformatics. All bioinformatics analysis was carried out using publically available data sets from the R2 
database (r2.amc.nl). Specific datasets used for each figure are described in the corresponding figure legends. The 
datasets used were Roth (GSE3526)34; Pfister (GSE49243)47, Gilbertson (GSE37418)48,49; Northcott (GSE21140)35; 
MAGIC (GSE37382)50 and Cavalli (GSE85217)51.
Cell culture. The paediatric MB group 4 cell line CHLA-01-MED and the metastatic melanoma cell line 
MeWo were purchased from the American Type Culture Collection (ATCC). The cell lines RES256 and UW402 
were obtained through material transfer agreement with Dr. John Sibler, Seattle. Cell lines were DNA finger-
printed using an in-house method52 and compared to published genotypes where available to validate cell line 
identity. Cell lines were confirmed as mycoplasma free using the MycoAlert detection kit (Lonza). RES256 and 
UW402 cells were cultured in Dulbecco’s modified Eagle’s media (DMEM) (Gibco) supplemented with 10% 
foetal bovine serum (FBS) (Sigma). CHLA-01-MED was cultured according to distributor’s recommendation 
as a suspension culture in DMEM f-12 (ATCC) supplemented with 2% v/v B27 supplement (Invitrogen) and 
20 ng/mL FGF-2 and EGF (Miltenyi Biotech). MeWo was cultured according to distributor’s recommendation in 
minimum essential media (MEM; ATCC) supplemented with 10% FCS. Cells transfected with pCMV-TetOn3G 
were selected with 1 mg/mL G-418 (Source Bioscience), cells also transfected with pTRE3G-IRES and linear 
puromycin marker constructs were selected with 0.5 ng/mL puromycin (Life technologies). To induce expression 
cells were cultured in the presence of 1 µg/mL doxycycline (Clontech) for 48 hours in a humidified 5% CO2 37 °C 
incubator. Transfected clones were cultured in DMEM supplemented with 10% tetracycline-free FCS (Clontech).
Cloning. pCMV-TetOn3G and pTRE3G-IRES constructs were purchased from Clontech. EGFP, SIAE and 
SIAE S127A genes were synthesised by Eurofins Genomics. Each gene was amplified using CloneAmp PCR pre-
mix (Clontech) and the following primers which contain 15 bp overhang regions complementary to the line-
arized plasmid and restriction sites SIAE-F CCCTCGTAAAGTCGACATGGTCGCGCCGGGGCTTGTACTC; 
SIAE-R GGAGAGGGGCCGGCCGTCATTTAGCAACATTGCTCTGATG; EGFP-F GCCGGATATCACGCG 
TATGGTGAGCAAGGGCGAGGAGCTG; EGFP-R CAGTTACATTGGATCCTTACTTGTACAGCTCGTC 
CATGCC.
PCR cycling conditions were as follows; melting temperature 98 °C for 10 seconds, annealing temperature 
55 °C for 15 seconds, extension temperature 72 °C for 8 seconds for 35 cycles. The PCR products were spin column 
purified using the Nucleospin PCR purification kit according to manufacturer’s instructions (Clontech). The 
pTRE3G-IRES constructs were then linearized using restriction digests with SalI and EagI for EGFP cloning, or 
MluI/BamHI for SIAE or S127A cloning (NEB) and then spin column purified as previous. HD EcoDry InFusion 
cloning (Clontech) was then used to insert amplified genes into linearized constructs by incubation in a BioRad 
Thermal cycler for 15 minutes at 37 °C, followed by 15 minutes at 50 °C. The resulting DNA was transformed into 
Stellar competent E. coli (Clontech) according to manufacturer’s instructions. Plasmid DNA obtained was iso-
lated using a PureYield plasmid miniprep kit (Promega) and sequenced by Eurofins genomics to ensure sequence 
integration and accuracy.
Generation of double stable transfectants. Cell lines were transfected Xfect transfection reagent 
(Clontech) with pCMV-TetOn3G constructs (Clontech) and selected with 1 mg/mL G-418 (Biochrom). Resulting 
colonies were expanded and screened for leaky expression and inducibility by transient transfection with 
tet-responsive luciferase constructs pTRE3G-Luc (Clontech) in the presence and absence of 1 μg/mL doxycycline 
(Clontech) for 48 hours to induce gene expression. The samples were then assayed using the Dual Luciferase 
assay kit (Promega) according to manufacturer’s instructions. The selected clone was then co-transfected with 
pTRE3G-IRES containing cloned genes of interest and with a linear puromycin marker. Clones were selected 
with 0.5 μg/mL puromycin (Fisher) and selected using fluorescence microscopy (selection using EGFP reporter). 
Constructs were tet-responsive- pTRE3G-IRES-EGFP (empty vector control); pTRE3G-IRES-EGFP-SIAE 
(which generated two clones) or pTRE3G-IRES-EGFP-SIAE-S127A (active site mutant).
sIAe antibody production. An immunogenic candidate SIAE peptide was designed using 
NHLBI-AbDesigner software. Alta Bioscience Ltd produced the selected 17 amino acid peptide sequence 
(SSDLSKKSSDDGFPQIR) which had optimal immunogenicity and minimal cross-reactivity. The SIAE peptide 
was used to produce antibodies in sheep by National Health Service (NHS) Scotland. Sheep were bled and the 
antibody was purified for use in this project.
Protein isolation and western blot analysis. Protein was extracted 48 hours after doxycycline treat-
ment using M-PER lysis buffer (Thermo) supplemented with 1% phosphatase and protease inhibitors (Thermo). 
Protein concentrations were determined using BCA assay (Thermo) on an Optima plate reader (BMG Labtech). 
Proteins were then resolved using 10% Tris-gycine gels (Thermo). After separation, protein (50 µg) was trans-
ferred to a PVDF-ImmunoBlot membrane (BioRad) and blocked in 5% non-fat milk for 1 hour at room temper-
ature on a rocking platform. The blots were then incubated with primary antibody overnight at 4°C on a rocking 
platform. Antibodies were applied as follows: sheep anti-human SIAE (Custom, see antibody production) 3 ug/
mL and mouse anti-human β-actin (Sigma). Subsequently, the blots were washed five times in Tris-buffered saline 
containing 0.05% Tween-20 before and after 1 hour of incubation at room temperature with Licor 800CW infared 
secondary antibodies. Blots were performed in dupicate. β-actin was used to control for protein loading. Blots 
were imaged by Licor Odyssey Clx technology using Image Studio 5 software.
Flow cytometry. Expression of GD3 and GD3A was determined by flow cytometry. Cells were cultured in 
1.5 mL media and treated as per experiment, cells were seeded at 250,000 cells per well. Cells were harvested and 
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centrifuged at 300 rcf for 5 minutes at 4 °C in an Eppendorf 5145R centrifuge. Cells were then resuspended in 
1 mL ice-cold phosphate buffered saline (PBS; Sigma) supplemented with 5% normal goat serum (NGS; Biosera) 
and centrifuged using the same conditions as previously described, twice (wash step). Cells were permeabilized 
using 250 µL Cytofix/Cytoperm solution (BD Biosciences) at 4 °C for 20 minutes before incubating with primary 
antibody for 30 minutes at 4 °C (20 µg/mL mouse anti-human GD3 clone MB3.6 (Millipore) or 10 µg/mL mouse 
anti-human 9-O-acetyl GD3 (Thermo)) in the presence of 5% goat serum and 0.1% saponin (Sigma). The wash 
step was repeated. Next cells were incubated with 4 μg/mL goat anti-mouse secondary antibody, AlexaFluor 
488 (Invitrogen) in the presence of 0.1% saponin for 15 minutes at 4 °C. The wash step was repeated. Cells were 
then resuspsended in 300 µL cold PBS supplemented with 2% NGS and 0.01% sodium azide (Sigma), and fil-
tered using 20 µm nylon mesh filter (Millipore). Expression data were collected using a 4-color multiparameter 
fluorescence-activated cell sorting (FACS) Calibur flow cytometer (BD Biosciences), and acquisition and analysis 
of data were carried out using CellQuest Pro Software.
JC-1 Assay. Cells were seeded at 250,000 per well, in the presence and absence of doxycycline. After 48 hours, 
cells were harvested and centrifuged at 300 rcf for 5 minutes. Each sample, re-suspended cell in 1 ml of PBS 
(Sigma) and 12.5 µl of JC-1 (Chemometec) at a final concentration of 2.5 µg/ml and incubated for 10 minutes at 
37 °C. The stained cells were centrifuged at 400 rcf for 5 minutes at room temperature and remove the supernatant 
completely without disturbing the cell pellet. The cell pellet was re-suspended in 1 ml PBS by pipetting, centrifuge 
at 400 rcf for 5 minutes room temperature and the supernatant removed completely without disturbing the cell 
pellet, this is repeated a second time. Finally, the cell pellet is re-suspended in 0.25 ml DAPI (1 µg/ml) and fluores-
cence intensity measured immediately in a black 96 well plate, Green (Excitation/Emission 485 nm/520 nm) and 
Red (Excitation/Emission 544 nm/590 nm) using BMG OPTIMA PolarStar. In healthy cells, the negative charge 
established by the intact mitochondrial membrane potential causes an accumulation of JC-1 in the mitochondrial 
matrix. At high concentrations JC-1 forms aggregates and become red fluorescent. In apoptotic cells the mito-
chondrial potential collapses and JC-1 localises to the cytosol in its monomeric green fluorescent form. The ratio 
of aggregates (red) to monomers (green) was calculated.
Trypan blue exclusion assay. RES256 cells were plated at 250,000 cells in 6-well plates. After 24 h of adher-
ence cells were counted using the trypan blue solution (Life Technologies) according to manufacturer’s protocol. 
The cells were then counted using the automated Countess II cell counter (Life Technologies). Cells were then 
treated with doxycycline for 96 h before cells were counted using the method previously described. Cell counts 
were normalised to time 0 h to normalise for proliferation differences between clones prior to doxycycline treat-
ment and expressed as percentage viable.
esterase activity assay. The enzymatic activity of SIAE of transfected cells was determined using the gen-
eral esterase artificial substrate 4-nitrophenyl acetate (pNPA) (Sigma), the release of the product 4-nitrophenol 
(pNP) (Sigma) can be measured at 405 nm, as described28. Cells were seeded at 2,500 cells per well in 100 μL clear 
media in 96 well plates, in the presence and absence of doxycycline. Firstly, a 20 mM stock of pNPA was prepared 
in DMSO. Media was removed and the cells were washed twice with PBS. In each well, 220ul of Phosphate buffer 
(50 mM, pH 7.4) was added, pNPA was added using on board injectors to a final concentration of 0.1 mM or 
0.2 mM and absorbance was measured at 410 nm using BMG OPTIMA PolarStar. A standard curve was generated 
using pNP (0.025–0.2 mM).
Chemotherapy experiments. Treatment of cells with etoposide was carried out by plating EGFP, SIAE 
and SIAE-S127A expressing clones at 2,500 cells per well in 100 μL clear media in 96 well plates. Cells were plated 
in the presence and absence of doxycycline. After 48 of doxycycline treatment cells were treated with Etoposide 
(Sigma) prepared in dimethylsulfoxide (DMSO; Sigma). Concentrations ranged from 1 μM to 14 μM in 1 μM 
increases. Untreated cells and vehicle controls were included. Cells were treated for 72 hours post-chemotherapy 
addition. Phase-contrast images were taken and MTS assays using CellTiter 96 AQueous One Solution (Promega) 
were carried out at the end of the time course according to manufacturer’s instructions. Plates were incubated 
at 37 °C for 3 hours. The absorbance was then read at 490 nm using the BMG labtech POLARstar Optima plate 
reader.
statistics. All experiments were carried out in triplicate unless otherwise stated. All statistical analysis was 
carried out using GraphPad Prism 6 software, individual statistical tests are outlined as appropriate in figure leg-
ends. P-values less than 0.05 were considered significant.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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